Fremont, CA – April 25th, 2011 – Nitinol Devices & Components (NDC), a pioneer in Nitinol materials and manufacturing processes for the medical, industrial and consumer markets, has closed a $20 million growth equity financing with Ampersand Capital Partners (Ampersand). Terms of the transaction were not disclosed.
Since 1991, NDC’s engineers and scientists have designed and developed some of the world’s most successful Nitinol devices. NDC has unmatched Nitinol knowledge and experience, from providing highest purity Nitinol materials that are produced to the most stringent mechanical specifications, to manufacturing the most delicate and intricate implantable Nitinol devices and components on the market.
According to Tom Duerig, President and CEO of NDC, “Ampersand’s combined focus on materials science leadership and medical device outsourcing made them the logical choice to be NDC’s financial partner. Our working relationships with two of Ampersand’s other device outsourcing portfolio companies also helped to make us very comfortable partnering with Ampersand as our sole institutional investor.”
“We welcome the opportunity to collaborate with this exceptional management team, and we look forward to helping the company continue its impressive record of growth and achievement” said Rick Charpie, Founder and Managing Partner of Ampersand. “NDC fits squarely into our middle market growth investment profile. The company is a leader in the markets it serves, and is well positioned to capitalize on future acquisition and organic growth opportunities.”
As a result of this investment, Ampersand Partners Jared Bartok and Rick Charpie have joined the board of NDC.
NDC is a privately held medical device company headquartered in Fremont, CA, USA. Focused on the medical field, NDC provides manufacturing, research, development, regulatory and technical support on all aspects of Nitinol technology and processing, and is aggressively expanding its capabilities to meet the growing demand for its shape-memory and superelastic Nitinol products. For more information: http://www.nitinol.com.
Ampersand is a middle market private equity firm with a focus in two core Sectors: Healthcare and Industrial. Within this core, Ampersand targets growth equity opportunities where it can be the first institutional investor. Ampersand’s unique blend of private equity and operating skills positions the firm to build value and drive long-term performance by working in support of the portfolio company management teams. For more information: www.ampersandcapital.com.